STOCK TITAN
  1. Home
  2. News
  3. BDSX

Biodesix, Inc. - BDSX STOCK NEWS

Welcome to our dedicated news page for Biodesix (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on Biodesix .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biodesix 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biodesix 's position in the market.

News
Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023
Rhea-AI Summary
Biodesix, Inc. (Nasdaq: BDSX) will release financial results for Q3 2023 on November 7. A conference call and webcast will be held to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
conferences earnings
-
News
Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting
Rhea-AI Summary
Biodesix, Inc. announces new data on the clinical utility and real-world impact of Nodify CDT and Nodify XL2 tests in managing lung nodules. The Nodify XL2 test shows a 74% reduction in invasive procedures on benign nodules. The Nodify CDT test improves PET/CT imaging in identifying malignant nodules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
conferences
-
News
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
Rhea-AI Summary
Biodesix, Inc. announces two abstracts to be presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Lung Conference on Lung Cancer (WCLC). The first abstract shows that the VeriStrat host immune classifier can predict response to immune checkpoint inhibitor (ICI) regimens in patients with advanced stage non-small cell lung cancer (NSCLC). The second abstract highlights the performance of a pre-surgical Risk of Recurrence test in identifying patients with a high probability of recurrence in early stage NSCLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
News
Biodesix to Participate in Two Upcoming Investor Conferences in September
Rhea-AI Summary
Biodesix CEO to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
conferences
-
News
Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer
Rhea-AI Summary
Biodesix announces data demonstrating a 51% relative increase in cancer diagnosis rate for lung nodules with the use of Nodify XL2 test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
none
-
News
Biodesix Announces Second Quarter 2023 Results and Highlights
Rhea-AI Summary
Biodesix, Inc. announces record-setting second quarter results with $11.4 million in revenue, a 58% increase YoY, and a gross profit margin of 73%. The company also raised $27.5 million in equity funding through a private placement. Biodesix continues to publish data supporting the value of their lung diagnostics tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
earnings
News
Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference
Rhea-AI Summary
Biodesix CEO, Scott Hutton, will present and host investor meetings at the Canaccord Genuity 43rd Annual Growth Conference from August 7-10, 2023. The fireside chat will be webcast live and available for replay on Biodesix's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.17%
Tags
conferences
-
News
Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
conferences earnings
-
News
Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
Rhea-AI Summary
Biodesix, Inc. announced that the ORACLE study achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by Nodify XL2® experiencing invasive procedures. The study showed that patients with benign nodules managed with the Nodify XL2 test were 74% less likely to undergo an unnecessary invasive procedure compared to the control group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
clinical trial
News
Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services
Rhea-AI Summary
Biodesix, Inc. announced that the Nodify CDT Test has been designated as an Advanced Diagnostic Laboratory Test (ADLT) by CMS, effective June 30, 2023. The Nodify CDT test is used in combination with the Nodify XL2 test for lung cancer diagnosis and treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
none
Stock BDSX logo
Biodesix, Inc.

Nasdaq:BDSX

BDSX Rankings

#4006 Ranked by Market Cap
#548 Ranked by Stock Gains
N/A Ranked by Dividends

BDSX Stock Data

143.36M
39.12M
59.44%
13.73%
0.29%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United States of America
BOULDER

About BDSX

biodesix develops and commercializes blood-based molecular diagnostic tests that advance the standard of care in oncology. our diagnostics help patients and their doctors make more informed decisions about treatment based on a patient's unique molecular profile. we're advancing precision medicine by helping physicians provide the right patient with the right treatment at the right time, and move patients to optimal treatment faster. we partner with pharmaceutical companies to develop tests that accelerate pipelines and bring effective therapies to market. our two commercialized tests, veristrat® & genestrat™, offer results in 72 hours. no tissue is required.